Empagliflozin decreases myocardial cytoplasmic Na⁺ through inhibition of the cardiac Na⁺/H⁺ exchanger in rats and rabbits.

ABSTRACT:

Aims/hypothesis

Empagliflozin (EMPA), an inhibitor of the renal sodium-glucose cotransporter (SGLT) 2, reduces the risk of cardiovascular death in patients with type 2 diabetes. The underlying mechanism of this effect is unknown. Elevated cardiac cytoplasmic Na⁺ ([Na⁺]_c) and Ca²⁺ ([Ca²⁺]_c) concentrations and decreased mitochondrial Ca²⁺ concentration ([Ca²⁺]_m) are drivers of heart failure and cardiac death. We therefore hypothesised that EMPA would directly modify [Na⁺]_c, [Ca²⁺]_c and [Ca²⁺]_m in cardiomyocytes.

Methods

[Na⁺]_c, [Ca²⁺]_c, [Ca ²⁺]_m and

SUBMITTER: Baartscheer A 

PROVIDER: S-EPMC6518059 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature